Profil

Executive Summary

Profil is a Germany-based clinical research organization (CRO) and the world’s leading full-service CRO specializing exclusively in diabetes and obesity research. Founded in 1998 as a spin-off from an academic group, the company has built a reputation for expertise in early-phase clinical trials, including pharmacodynamics, pharmacokinetics, and biosimilar studies. Profil is particularly renowned for its mastery of the glucose clamp technique, a gold-standard method for assessing insulin sensitivity and glucose metabolism. With a focus on metabolic diseases, the company serves a broad range of pharmaceutical and biotech clients, offering sophisticated trial services that reduce development risk and accelerate timelines. As a private, specialized CRO, Profil is well-positioned to benefit from the growing global demand for diabetes and obesity treatments, driven by rising prevalence of metabolic disorders and a robust pipeline of novel therapies. Its deep domain expertise and established infrastructure provide a competitive moat against larger, generalist CROs, though limited public financial data makes it challenging to quantify its market share or growth trajectory.

Upcoming Catalysts (preview)

• Q3 2026New partnership with a major pharma company for obesity Phase I trials60% success
• Q4 2026Expansion of service capabilities into metabolic syndrome or NASH50% success
• TBDPotential strategic acquisition or investment from a larger CRO seeking specialized capabilities30% success